This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with Advanced Colorectal Cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-05; most recent amendment 2026-04-13.